Suppression of polyethylene particle-induced osteolysis by exogenous osteoprotegerin

Journal of Biomedical Materials Research - Part A

Volumn 75, Issue 2, 2005, Pages 288-294

  Von Knoch, Fabian ^a   Heckelei, Anja ^b   Wedemeyer, Christian ^b   Saxler, Guido ^b   Hilken, Gero ^b   Brankamp, Jochen ^b   Sterner, Thomas ^b   Landgraeber, Stefan ^b   Henschke, Frank ^c   Löer, Franz ^b   Von Knoch, Marius ^b  

^a Kantonsspital Chur ^*  (Switzerland)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c Pathologisches Inst Am J   (Germany)

Author keywords

Calvarial model; Osteoclastogenesis; Osteolysis; Osteoprotegerin; Polyethylene particles

Indexed keywords

BONE; IMPLANTS (SURGICAL); JOINTS (ANATOMY); SURGERY;

CALVARIAL MODEL; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPROTEGERIN; POLYETHYLENE PARTICLES;

POLYETHYLENES;

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; POLYETHYLENE; ULTRA HIGH MOLECULAR WEIGHT POLYETHYLENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALVARIA; CONTROLLED STUDY; FEMALE; GIEMSA STAIN; IMPLANTATION; MACROPHAGE ACTIVATION; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOLYSIS; PARTICLE SIZE; PROSTHESIS FAILURE; PROSTHESIS LOOSENING; TOTAL HIP PROSTHESIS;

ANIMALS; BIOCOMPATIBLE MATERIALS; FEMALE; GLYCOPROTEINS; MALE; MATERIALS TESTING; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; OSTEOCLASTS; OSTEOLYSIS; OSTEOPROTEGERIN; PARTICLE SIZE; POLYETHYLENES; PROSTHESIS FAILURE; RANDOM ALLOCATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS; SKULL;

EID: 26844543513     PISSN: 00219304     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbm.a.30441     Document Type: Article

References (34)

1. Sinha RK, Shanbhag AS, Maloney WJ, Hasselman CT, Rubash HE. Osteolysis: cause and effect. Instr Course Lect 1998;47:307-320.
2. Goldring SR, Schiller AL, Roelke M, Rourke CM, O'Neill DA, Harris WH. The synovial-like membrane at the bone-cement interface in loose total hip replacements and its proposed role in bone lysis. J Bone Joint Surg 1983;65A:575-584.
3. Willert HG, Semlitsch M. Reactions of the articular capsule to wear products of artificial joint prostheses. J Biomed Mater Res 1977;11:157-164.
4. Jones LC, Hungerford DS. Cement disease. Clin Orthop 1987; 225:192-206.
5. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-342.
6. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176.
7. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trau G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309-319.
8. Crotti TN, Smith MD, Findlay DM, Zreiqat H, Ahern MJ, Weedon H, Hatzinikolous G, Capone M, Holding C, Haynes DR. Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin. Biomaterials 2004;25:565-573.
9. Mandelin J, Li TF, Liljestrom M, Kroon ME, Hanemaaijer R, Santavirta S, Konttinen YT. Imbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacement. J Bone Joint Surg 2003;85B:1196-1201.
10. Haynes DR, Crotti TN, Potter AE, Loric M, Atkins GJ, Howie DW, Findlay DM. The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. J Bone Joint Surg 2001;83B:902-911.
11. Kim KJ, Kotake S, Udagawa N, Ida H, Ishii M, Takei I, Kubo T, Takagi M. Osteoprotegerin inhibits in vitro mouse osteoclast formation induced by joint fluid from failed total hip arthroplasty. J Biomed Mater Res 2001;58:393-400.
12. Clohisy JC, Frazier E, Hirayama T, Abu-Amer Y. RANKL is an essential cytokine mediator of polymethylmethacrylate particle-induced osteoclastogenesis. J Orthop Res 2003;21:202-212.
13. Baumann B, Rader CP, Seufert J, Noth U, Rolf O, Eulert J, Jakob F. Effects of polyethylene and TiAlV wear particles on expression of RANK, RANKL and OPG mRNA. Acta Orthop Scand 2004;75:295-302.
14. Premnath V, Bellare A, Merrill EW, Jasty MJ, Harris WH. Molecular rearrangements in ultra high molecular weight polyethylene after irradiation and long-term storage in air. Polymer 1999;40:2215-2229.
15. McKellop H, Shen FW, Lu B, Campbell P, Salovey R. Development of an extremely wear-resistant ultra high molecular weight polyethylene for total hip replacements. J Orthop Res 1999;17:157-167.
16. Muratoglu OK, Bragdon CR, O'Connor DO, Jasty M, Harris WH. A novel method of cross-linking ultra-high-molecular-weight polyethylene to improve wear, reduce oxidation, and retain mechanical properties. Recipient of the 1999 HAP Paul Award. J Arthroplasty 2001;16:149-160.
17. Shanbhag AS, Hasselman CT, Rubash HE. The John Charnley Award. Inhibition of wear debris mediated osteolysis in a canine total hip arthroplasty model. Clin Orthop 1997;344:33-43.
18. von Knoch M, Wedemeyer C, Pingsmann A, von Knoch F, Hilken G, Sprecher C, Henschke F, Barden B, Loer F. The decrease of particle-induced osteolysis after a single dose of bisphosphonate. Biomaterials 2005;26:1803-1808.
19. von Knoch F, Heckelei A, Wedemeyer C, Saxler G, Hilken G, Henschke F, Loer F, von Knoch M. The effect of simvastatin on polyethylene particle-induced osteolysis. Biomaterials 2005;26:3549-3555.
20. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001;16:348-360.
21. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, Harousseau JL, Lipton A, Mariette X, Williams CD, Nakanishi A, Holloway D, Martin SW, Dunstan CR, Bekker PJ. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003;97:887-892.
22. Goater JJ, O'Keefe RJ, Rosier RN, Puzas JE, Schwarz EM. Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis. J Orthop Res 2002;20:169-173.
23. Ulrich-Vinther M, Carmody EE, Goater JJ, S balle K, O'Keefe RJ, Schwarz EM. Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis. J Bone Joint Surg 2002;84A:1405-1412.
24. Yang SY, Mayton L, Wu B, Goater JJ, Schwarz EM, Wooley PH. Adeno-associated virus-mediated osteoprotegerin gene transfer protects against particulate polyethylene-induced osteolysis in a murine model. Arthritis Rheum 2002;46:2514-2523.
25. von Knoch M, Jewison DE, Sibonga JD, Sprecher C, Morrey BF, Loer F, Berry DJ, Scully SP. The effectiveness of polyethylene versus titanium particles in inducing osteolysis in vivo. J Orthop Res 2004;22:237-243.
26. Merkel KD, Erdmann JM, McHugh KP, Abu-Amer Y, Ross FP, Teitelbaum SL. Tumor necrosis factor-alpha mediates orthopedic implant osteolysis. Am J Pathol 1999;154:203-210.
27. Morony S, Capparelli C, Lee R, Shimamoto G, Boone T, Lacey DL, Dunstan CR. A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3. J Bone Miner Res 1999;14:1478-1485.
28. Redlich K, Gortz B, Hayer S, Zwerina J, Doerr N, Kostenuik P, Bergmeister H, Kollias G, Steiner G, Smolen JS, Schert G. Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis. Am J Pathol 2004;164:543-555.
29. von Knoch M, Sprecher C, Barden B, Saxler G, Loer F, Wimmer M. [Size and shape of commercially available polyethylene particles for in-vitro and in-vivo-experiments]. Z Orthop Ihre Grenzgeb 2004;142:366-370.
30. Schwarz EM, Lu AP, Goater JJ, Benz EB, Kollias G, Rosier RN, Puzas JE, O'Keefe RJ. Tumor necrosis factor-alpha/nuclear transcription factor-kappaB signaling in periprosthetic osteolysis. J Orthop Res 2000;18:472-480.
31. Liu CC, Sherrard DJ, Maloney NA, Howard GA. Reactivation of inhibited bone acid phosphatase and its significance in bone histomorphometry. J Histochem Cytochem 1987;35: 1355-1363.
32. Childs LM, Goater JJ, O'Keefe RJ, Schwarz EM. Effect of anti-tumor necrosis factor-alpha gene therapy on wear debris-induced osteolysis. J Bone Joint Surg 2001;83A:1789-1797.
33. Kurtz SM, Muratoglu OK, Evans M, Edidin AA. Advances in the processing, sterilization, and crosslinking of ultra-high molecular weight polyethylene for total joint arthroplasty. Biomaterials 1999;20:1659-1688.
34. Willert HG, Bertram H, Buchhorn GH. Osteolysis in alloarthroplasty of the hip. The role of ultra-high molecular weight polyethylene wear particles. Clin Orthop 1990;258:95-107.